INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Skyhawk Therapeutics

Carisma Therapeutics

Entrada Therapeutics

Pliant Therapeutics

Pyxis Oncology

Dragonfly Therapeutics

Freenome

ImCheck Therapeutics

Dice Therapeutics

Orbus Therapeutics

View Full Portfolio

Featured News

Press Release | November 23, 2021

Dragonfly Announces Merck Opt-In on Second TriNKET

Read More

News | November 12, 2021

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

Read More

News | October 20, 2021

imCheck Publishes Comprehensive Overview of the Developmenet Resumts of its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Cells in Science Translational Medicine

Read More

View All